Comparative Analysis of Clinical Signs in Patients with Covid-19 Who Suffer Chronic Viral Hepatitis C

Abstract

The global pandemic of the new coronavirus infection (COVID-19), which began in December 2019 in Uhan (China), has spread worldwide. On 11 March 2020, the World Health Organization announced the outbreak of the SARS CoV-2 pandemic due to the constant number of cases outside China.  [1].  Rapid and decisive measures are being taken in our country to effectively combat the coronavirus pandemic, which is spreading rapidly around the world. Particular attention is paid to such important aspects as preventing the spread of coronavirus infection, effective treatment of patients with the disease, and conducting laboratory tests. Patients with chronic liver diseases required increased attention of doctors during the epidemic, since against the background of an exacerbation of their diseases, not only the risk of contracting a viral infection of COVID - 19 increased, but also its aggravation. (Mekhtiev.S.N and co-author. 2020 ).  Severe liver damage during the severe course of COVID – 19 is diagnosed with a severe course of the disease. Patients with COVID - 19, confirmed by serious liver damage, experience an increase in high biochemical indicators. At the height of the disease, thrombocytopenia is observed. An increase in serum aminotransferase, creatinkinase and lactatdegydrogenase activity is detected. [10].  Literature has shown that patients with severe covid – 19 manifestations are at higher ALT levels, lower platelet and albumin numbers, and higher risk of death. Data analysis shows that the frequency of cases of impaired liver function increases in proportion to the severity of COVID-19 flow.   Apparently, an increase in alt, hypoalbuminemia and thrombocytopenia are unfavorable factors in the prognosis of the disease. Analysis of the clinical picture of COVID-19 has shown that SARSCoV-2 has significant effects for SJK (chronic liver diseases).  Patients with viral etiology are more susceptible to liver damage, which is likely due to increased replication of hepatitis V and C viruses during SARSCoV-2 infection.  The presence of an Associated side disease (diabetes, cardiovascular diseases) tends to develop a severe form of COVID-19 in patients. [2].  Today, there is no clear data on whether patients with chronic hepatitis C have a higher risk of contracting COVID-19 compared to other diseases. At the same time, serious complications, if it is not possible to prevent COVID-19 infection, then the disease develops rapidly in them. [5].   Even if hepatitis C has been successfully treated in particular, it increases the chances of severe covid-19 passing. Therefore, against the background of the COVID-19 pandemic, the problems of patients with chronic viral hepatitis C are unresolved and require study. In epidemic conditions, it is very important to effectively monitor patients with this pathology and continue to treat them health, as well as to carry out scientific research to reduce the problem in the health system and reduce the disease [2].